Cablivi CHMP Backing Helps Validate Sanofi's €3.9bn Ablynx Purchase
Cablivi is first therapeutic to receive positive CHMP opinion for treating acquired thrombotic thrombocytopenic purpura, a rare blood disorder.
You may also be interested in...
UCB and Fund+ are supporting a spin out from the renowned VIB research institute and ExeVir Bio CEO Torsten Mummenbrauer told Scrip that the firm's llama antibodies should be in the clinic for COVID-19 possibly by November.
The latest drug development news and highlights from our US FDA Performance Tracker.
Hours after getting the nod from the FDA for Cablivi, the French drugmaker has had an R&D pipeline overhaul and says it could potentially submit nine new medicines and 25 additional indications to regulatory authorities from 2019 to 2022.